<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Everest Medicines Ltd. ( (HK:1952) ) just unveiled an announcement. Everest Medicines has disclosed that non-executive director and honorary chairman Wei Fu, a substantial shareholder, has increased his stake in the company. Through a controlled entity, Fu bought 660,000 shares on the market on 14 May 2026 for about HK$20.7 million, paying an average of roughly HK$31.25 per share. The purchase signals Fu’s strong confidence in Everest Medicines’ future prospects and long-term development, and he has indicated he may further increase his holdings subject to regulatory compliance. The move may be seen by investors as an endorsement of the company’s outlook, though the board has urged shareholders and potential investors to exercise caution when trading the stock. The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page. More about Everest Medicines Ltd. Everest Medicines Limited is a biopharmaceutical company listed in Hong Kong, focusing on the development and commercialization of innovative medicines. The company targets high unmet medical needs in its key markets and is backed by a board comprising executive, non-executive and independent non-executive directors with extensive industry and investment experience. Average Trading Volume: 2,798,073 Technical Sentiment Signal: Sell Current Market Cap: HK$11.36B For an in-depth examination of 1952 stock, go to TipRanks’ Overview page.</div>

01952

159992

159316

520880

159570

159849

520690

159567

159506

Everest Medicines Ltd. announced that non-executive director Wei Fu has increased his stake by purchasing 660,000 shares for approximately HK$20.7 million, averaging HK$31.25 per share. This move reflects Fu's confidence in the company's future, with potential for further increases in holdings. However, the board advises caution to investors. The latest analyst rating for Everest Medicines (HK:1952) is a Hold, with a price target of HK$55.00. Everest Medicines focuses on developing innovative medicines for unmet medical needs and has a market cap of HK$11.36B.

Tip Ranks

EVEREST MED

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Everest Medicines Director and Major Shareholder Raises Stake in Company